This clinical trial looks into treating advanced cancers using a combination of therapies. The diseases being studied in this trial include various types of advanced malignancies, which are serious forms of cancer that have progressed to an advanced stage. The study focuses on a therapy that includes a main drug, atezolizumab, and additional drugs being used as comparators. Atezolizumab is a type of drug that helps the immune system attack cancer cells, and it’s given to patients intravenously, meaning it’s delivered directly into a vein. The additional drugs tested in this extension of the study include Sutent, Paclitaxel, Alecensa, and Cotellic.

The goal of this study is to continue providing the treatment to patients who have already participated in earlier phases of similar studies but still need ongoing therapy since they cannot access these medicines locally. This means the therapy will continue for patients who are still benefiting from it according to assessments by their doctors.

The study does not provide detailed procedures but involves using these medicines to see if the patients continue to respond positively to the treatment therapies. This ongoing treatment will allow the observation of the treatments’ effects over a longer period and help determine the best use of these drugs in managing cancer. Some patients might be given a placebo, which is a substance with no therapeutic effect used in trials to test the effectiveness of another drug.